A SPECT tracer version of evuzamitide for imaging systemic amyloidosis
While PET is a powerful technique, SPECT allows for widespread utilization and ease of use
#CardioSky #ACC25
#MEDIQACC25 #Cardiology
0
0
0
0
Hashtag
#MEDIQACC25
Advertisement · 728 × 90
We presented updated data from 97 patients who underwent I124-evuzamitide PET/MRI imaging. Excellent diagnostic performance. Even when we used LV blood pool the SUVR seperation remains robust. Desc aorta is even more impressive. Some examples.
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
0
0
1
0
Automated quantification of 124I-evuzamitide organ uptake on PET/CT in systemic amyloidosis
#CardioSky #ACC25 #MEDIQACC25 #Cardiology
0
0
1
0
I missed this presentation. Higher than we would have expected in terms of positive rate in carpal tunnel release. Important data
#ACC25 #CardioSky
#MEDIQACC25 #Cardiology
0
0
1
0
Another analysis from ATTRIBUTE-CM looking at variant vs wild type ATTR-CM. Reminder this was a trial of acoramidis vs placebo.
No interaction --> effect very consistent in both variant and wild type
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Some more data with insights into the different groups within HELIOS-B trial of vutrisiran vs placebo.
#ACC25 #CardioSky
#MEDIQACC25 #Cardiology
0
0
1
0
More data from Helios B trial of vutrisiran vs placebo in ATTR CM
Treatment effect across the range of disease severity markers
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Interesting data on the early serum TTR increase in response to acoramidis in ATTribute-CM and outcomes -- more and more data on TTR level as a PD marker will be very useful
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
A mechanistic study that caught my attention - great insights here
Tafamidis and snRNA-seq
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Serum TTR as a PD marker for stabilization - here are data from ATTRIBUTE-CM showing no further increase in serum TTR with the addition of tafamidis
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Further analysis from ATTRibute-CM utilizing different NTproBNP cut offs as a marker of disease severity, and evaluating outcomes/consistency of treatment effect
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Responders analysis - acoramidis vs placebo for improving NYHA class from the ATTRibute-CM
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Kicking off our session on the multimodality imaging in cardiac #amyloidosis
#ACC25 #CardioSky
#MEDIQACC25 #Cardiology
Dr. Dia Smiley presenting a case of T60A where #HDP bone scintigraphy was negative, while biopsy was positive
Keep it in my - false negatives exist
0
0
1
0
0
0
1
0
Small study but ECV relationship to amyloid burden with an interaction with T2 relaxation time
By Brett Sperry, MD
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
1
0
1
0
A possible working frame why PYP/HDP/DPD uptake decrease over time while cardiac structure/ECV don't change presented by
Brett SperryMD
Sarah Cuddy
Sharmila Dorbala
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
0
0
1
0
It can get complicated
How to measure amyloid burden
By Brett Sperry, MD
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
1
0
1
0
Brett Sperry, MD, on the cascade of #transthyretin #amyloidosis and targeting it
#ACC25
#MEDIQACC25
#CardioSky
#Cardiology
1
0
1
0
With the delays in diagnosis
Maybe the solution is systematic screening in populations at risk
#ACC25
#MEDIQACC25
#CardioSky #Cardiology
Firas Al Badarin's work continued.
0
0
1
0
How does Firas Al Badarin diagnose transthyretin #cardiac #amyloidosis
Recognition is most important
- rule out AL
- bone scintigraphy
- TTR gene sequencing
- selective tissue sampling
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
1
0
1
0
Adding #Whycmr to the mix of risk in patients with #ATTR #cardiomyopathy
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
0
0
1
0
Relationship between echo parameters and clinical outcomes in #HELIOS-B
#ACC25 #CardioSky
#MEDIQACC25 #Cardiology
0
0
1
0
A further dive into the primary efficacy endpoint in ATTRibute-CM
#ACC25 #CardioSky
#MEDIQACC25 #Cardiology
0
0
1
0
Identification of #ATTR #CM using an AI model with ECG and #echofirst by Rohan Khera, et al
#ACC25 #CardioSky #MEDIQACC25 #Cardiology
0
0
1
0
Joshua Mitchell presents on the changing demographics and prevalence of #ATTR #CM in the US
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
0
0
1
0
Plasma proteomic profiling in patients with #ATTR #CM as compared to other LVH etiologies
#ACC25
#CardioSky
#MEDIQACC25
#Cardiology
0
0
1
0
0
0
1
0
Stages of disease
We are diagnosing patients at a different point in their heart failure journey
#ACC25 #MEDIQACC25 #Cardiology #CardioSky
0
0
1
0
So 3 options approved to date
Tafamidis
Acoramidis
Vutrisiran
We can't tell which is superior
How can one think about it?
#ACC25 #MEDIQACC25 #Cardiology #CardioSky
0
0
1
0